Company Update (NASDAQ:ARWR): Arrowhead Pharmaceuticals Inc Reports Fiscal 2016 Second Quarter Results

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced financial results for its fiscal 2016 second quarter ended March 31, 2016. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.

Fiscal 2016 Second Quarter and Recent Company Highlights

Corporate Events

  • Completed corporate name change to Arrowhead Pharmaceuticals, Inc. to better reflect the company’s stage of development and launched a new website at with an updated corporate identity


  • Began dosing patients in three Phase 2b studies: the MONARCH study, 2007 long-term extension, and 2001 open-label extension
  • Presented promising ARC-520 hepatitis B data at The International Liver Congress™ 2016, including the following key findings:
    • ARC-520 and entecavir produced rapid HBV DNA suppression with all hepatitis B e-antigen (HBeAg) positive, treatment naïve patients achieving serum HBV DNA reductions of up to 5.5 log (99.9997%), and all HBeAg negative, treatment naïve patients achieving reductions that put them below the limit of quantitation
    • ARC-520 effectively inhibited HBV cccDNA-derived mRNA with observed viral protein reduction in HBV patients of up to 2.0 log (99%) after a single dose
    • ARC-520 had a long duration of effect with HBsAg still reduced by 83% after 2 months and 75% after 3 months, which is the final time point of the study, after a single dose
    • Based on HBsAg epitope profile analysis, poster authors and Arrowhead collaborators had previously identified a predictive hepatitis B surface-antigen (HBsAg) Clearance Profile associated with HBsAg clearance in antiviral therapy cohorts
    • There was a significant association between the development of an HBsAg Clearance Profile and ARC-520 therapy in HBV patients
    • Complexed HBsAg antibodies (anti-HBs) were developed and detected in HBV patients treated with ARC-520, which may represent a recovery of the immune system response
    • After monthly administration of 6-11 doses of ARC-520 in chimpanzees chronically infected with HBV, the ARC-520 target site sequences remained virtually unchanged, indicating that no drug resistance developed during the treatment period


  • Filed for regulatory clearance to begin a Phase 1/2 first-in-human study to assess single and multiple-doses of ARC-521 in healthy volunteers and HBV patients


  • Received Orphan Drug Designation by the European Medicines Agency

Platform and Early Pipeline

  • Presented promising new preclinical data the 2016 American Academy of Allergy, Asthma & Immunology Annual Meeting suggesting that ARC-F12, an RNAi therapeutic that inhibits the production of Factor XII (F12), has the potential to treat hereditary angioedema and to prevent thrombosis
  • Presented data at the American Association for Cancer Research Annual Meeting 2016 (AACR16), showing that ARC-HIF2 inhibited tumor growth and promoted tumor cell death and structural degeneration in two different renal cell carcinoma tumor bearing mouse models
    • These data also show that important advancements are being made to Arrowhead’s Dynamic Polyconjugate™ (DPC™) delivery platform to include extra-hepatic targeting capabilities
  • Presented data on ARC-LPA, a preclinical development program targeting lipoprotein (a), or Lp(a), for the treatment of cardiovascular disease, at the Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2016 Scientific Sessions
    • These data show that ARC-LPA and Arrowhead’s new delivery vehicles designed for subcutaneous administration can induce deep target gene knockdown with long duration of effect that may enable monthly, bi-monthly, or even less frequent administration (Original Source)

Shares of Arrowhead Research closed today at $5.72, down $0.04 or -0.69%. ARWR has a 1-year high of $9.36 and a 1-year low of $3.07. The stock’s 50-day moving average is $5.50 and its 200-day moving average is $5.05.

On the ratings front, Arrowhead has been the subject of a number of recent research reports. In a report issued on March 31, Jefferies Co. analyst Eun Yang reiterated a Hold rating on ARWR, with a price target of $4, which implies a downside of 30.7% from current levels. Separately, on February 10, Piper Jaffray’s Edward Tenthoff maintained a Buy rating on the stock and has a price target of $13.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Eun Yang and Edward Tenthoff have a total average return of -5.4% and -9.2% respectively. Yang has a success rate of 49.2% and is ranked #3527 out of 3828 analysts, while Tenthoff has a success rate of 30.1% and is ranked #3691.

Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline includes clinical programs in chronic hepatitis B virus and partner based programs in obesity and oncology. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts